LanZhou Foci Pharmaceutical Co.,Ltd. (SHE:002644)
China · Delayed Price · Currency is CNY 8.72
-0.20 (-2.24%)
Apr 9, 2026, 3:04 PM CST
SHE:002644 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 915.53 | 977.45 | 1,158 | 1,041 | 809.39 |
Other Revenue | - | 2.78 | 5.45 | 1.58 | 8.25 |
| 915.53 | 980.23 | 1,163 | 1,042 | 817.64 | |
Revenue Growth (YoY) | -6.60% | -15.73% | 11.58% | 27.49% | 22.39% |
Cost of Revenue | 603.42 | 681.46 | 804.17 | 738.23 | 596.57 |
Gross Profit | 312.12 | 298.76 | 358.96 | 304.16 | 221.07 |
Selling, General & Admin | 175.21 | 184.21 | 236.74 | 181.6 | 131.27 |
Research & Development | 24.56 | 29.28 | 30.93 | 23.56 | 19.36 |
Other Operating Expenses | -13.58 | 11.37 | 13.32 | 14.53 | 14.82 |
Operating Expenses | 186.19 | 254.63 | 296.07 | 238.06 | 175.42 |
Operating Income | 125.93 | 44.13 | 62.9 | 66.1 | 45.65 |
Interest Expense | - | -0.83 | -1.24 | -1.35 | -0.95 |
Interest & Investment Income | - | 5.74 | 5.37 | 7.51 | 10.2 |
Currency Exchange Gain (Loss) | - | 0.3 | 1.08 | 2.15 | -0.33 |
Other Non Operating Income (Expenses) | -52.7 | -3.95 | -1.43 | -17.88 | -1.22 |
EBT Excluding Unusual Items | 73.23 | 45.38 | 66.67 | 56.53 | 53.36 |
Gain (Loss) on Sale of Investments | -13.54 | -7.23 | -4.49 | -1.3 | -0.85 |
Gain (Loss) on Sale of Assets | 7.13 | 0.04 | - | 0 | 27.18 |
Asset Writedown | -1.79 | - | -0 | -0.2 | -0.37 |
Legal Settlements | - | - | - | - | 0.01 |
Other Unusual Items | - | 30.94 | 19.46 | 75.68 | 31.48 |
Pretax Income | 65.03 | 69.14 | 81.64 | 130.72 | 110.81 |
Income Tax Expense | 18.08 | 7.47 | 13.52 | 21.37 | 17.3 |
Earnings From Continuing Operations | 46.96 | 61.67 | 68.12 | 109.35 | 93.52 |
Minority Interest in Earnings | 2.25 | -1.6 | -0.93 | -0.69 | -0.26 |
Net Income | 49.21 | 60.07 | 67.19 | 108.65 | 93.26 |
Net Income to Common | 49.21 | 60.07 | 67.19 | 108.65 | 93.26 |
Net Income Growth | -18.08% | -10.60% | -38.16% | 16.51% | -13.66% |
Shares Outstanding (Basic) | 510 | 511 | 511 | 511 | 511 |
Shares Outstanding (Diluted) | 510 | 511 | 511 | 511 | 511 |
Shares Change (YoY) | -0.07% | 0.05% | -0.01% | -0.03% | 0.00% |
EPS (Basic) | 0.10 | 0.12 | 0.13 | 0.21 | 0.18 |
EPS (Diluted) | 0.10 | 0.12 | 0.13 | 0.21 | 0.18 |
EPS Growth | -18.03% | -10.64% | -38.16% | 16.54% | -13.66% |
Free Cash Flow | 165.4 | 25.7 | 43.24 | 45.08 | -20.95 |
Free Cash Flow Per Share | 0.32 | 0.05 | 0.09 | 0.09 | -0.04 |
Dividend Per Share | - | 0.012 | 0.030 | 0.050 | 0.010 |
Dividend Growth | - | -60.00% | -40.00% | 400.00% | -91.67% |
Gross Margin | 34.09% | 30.48% | 30.86% | 29.18% | 27.04% |
Operating Margin | 13.75% | 4.50% | 5.41% | 6.34% | 5.58% |
Profit Margin | 5.38% | 6.13% | 5.78% | 10.42% | 11.41% |
Free Cash Flow Margin | 18.07% | 2.62% | 3.72% | 4.32% | -2.56% |
EBITDA | 180.02 | 93.76 | 114.29 | 114.96 | 93.58 |
EBITDA Margin | 19.66% | 9.56% | 9.83% | 11.03% | 11.45% |
D&A For EBITDA | 54.09 | 49.63 | 51.39 | 48.86 | 47.92 |
EBIT | 125.93 | 44.13 | 62.9 | 66.1 | 45.65 |
EBIT Margin | 13.75% | 4.50% | 5.41% | 6.34% | 5.58% |
Effective Tax Rate | 27.79% | 10.81% | 16.56% | 16.35% | 15.61% |
Revenue as Reported | - | 980.23 | 1,163 | 1,042 | 817.64 |
Advertising Expenses | - | 7.68 | 37.86 | 22.29 | 15.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.